EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cardiometabolic medication exposures and cognitive outcomes in Alzheimer’s disease

Yihan Wang, Benjamin Goudey, Colin L Masters, Liang Jin, Yijun Pan iD, Health and Aging Brain Study (HABS-HD) Study Team

Age and Ageing · 04.09.2026 · 55 (9)

DOI: 10.1093/ageing/afag263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Age and Ageing, online erschienen am 14.09.2026. Verfasst von Yihan Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, School of Translational Medicine, Monash University, 99 Commercial Rd., Melbourne, VIC 3004, Australia. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognition, Cognitive Dysfunction, Cardiovascular Agents. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIBIB NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People with dementia are often prescribed cardiometabolic medications; however, the impact of this medication exposome on cognitive trajectories remains unclear.

Methods

We analysed data from National Alzheimer’s Coordinating Center (n = 28 044), Australian Imaging, Biomarkers and Lifestyle study (n = 1708) and Health and Aging Brain Study: Health Disparities (n = 1425) to examine associations between seven classes of cardiometabolic medications and cognitive outcomes [CDR sum of boxes (CDR-SB)], using linear mixed-effects models with time-varying exposure. Subgroup analyses were conducted by sex, apolipoprotein E (APOE) ε4, baseline age group and four progression groups [i.e. non-progression, cognitively unimpaired-to-mild cognitive impairment (CU-to-MCI), CU/MCI-to-Alzheimer’s dementia (ADem) progression and ADem-stable group]. A meta-analysis was also performed.

Results

Angiotensin-converting enzyme inhibitors and metformin were associated with a slower cognitive decline. Diuretics showed comparable associations, although these effects were restricted to specific subgroups. Statins exhibited divergent, stage-specific associations, with inverse associations observed in the CU/MCI-to-ADem subgroup and positive associations in the ADem-stable subgroup. Angiotensin II receptor blockers were associated with a greater longitudinal increase in CDR-SB among participants in the non-progression subgroup. Calcium channel blockers showed limited subgroup-specific cognitive benefit but were also associated with an accelerated increase in CDR-SB over time. β-blockers demonstrated no consistent association with cognitive trajectories, with evidence of a lower CDR-SB slope observed only in a cohort-specific analysis.

Discussion

Future research should incorporate pharmacy-verified medication exposure, explicit dosing information and dynamically modelled trajectories, while routinely assessing baseline and follow-up cognitive outcomes in pharmacotherapy trials involving older adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitionCognitive DysfunctionCardiovascular AgentsHumansMaleFemaleDisease ProgressionAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsAustralia

Stichwörter der Autor:innen

Alzheimer’s diseaseangiotensin-converting enzyme inhibitorsantihypertensive drugsdementiametforminolder adults

Substanzen

Cardiovascular AgentsAngiotensin-Converting Enzyme InhibitorsHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Neuroscience, School of Translational Medicine, Monash University, 99 Commercial Rd., Melbourne, VIC 3004, Australia.
  • Australia BioCommons, The University of Melbourne, 21 Bedford Street, North Melbourne, Melbourne, VIC 3051, Australia.
  • The ARC Training Centre in Cognitive Computing for Medical Technologies, The University of Melbourne, 700 Swanston Street, Carlton, Melbourne, VIC 3053, Australia.
  • Alzheimer's Research Australia, The University of Western Australia, Nedlands, WA 6009, Australia.
  • School of Health and Biomedical Sciences, RMIT University, 30 Janefield Drive, Bundoora, Melbourne, VIC 3083, Australia.

ORCID-Profile: Yijun Pan

Förderung

  • NIBIB NIH HHS
  • NIA NIH HHS

Zitieren

APA

Wang, Y., Goudey, B., Masters, C. L., Jin, L., Pan, Y., & Health and Aging Brain Study (HABS-HD) Study Team (2026). Cardiometabolic medication exposures and cognitive outcomes in Alzheimer’s disease. Age and Ageing, 55(9). https://doi.org/10.1093/ageing/afag263

Vancouver

Wang Y, Goudey B, Masters CL, Jin L, Pan Y, Health and Aging Brain Study (HABS-HD) Study Team. Cardiometabolic medication exposures and cognitive outcomes in Alzheimer’s disease. Age and Ageing. 2026;55(9). doi:10.1093/ageing/afag263

BibTeX
@article{Wang2026,
  author = {Wang, Yihan and Goudey, Benjamin and Masters, Colin L and Jin, Liang and Pan, Yijun and Health and Aging Brain Study (HABS-HD) Study Team, Health and Aging Brain Study (HABS-HD) Study Team},
  title = {Cardiometabolic medication exposures and cognitive outcomes in Alzheimer’s disease},
  journal = {Age and Ageing},
  year = {2026},
  volume = {55},
  number = {9},
  doi = {10.1093/ageing/afag263}
}
Kostenlos starten →